Abstract
Due to its versatile nature and its corresponding anabolic and anticatabolic properties, insulin has been prohibited in sports since 1999. Numerous studies concerning its impact on glycogen formation, protein biosynthesis, and inhibition of protein breakdown have illustrated its importance for healthy humans and diabetics as well as elite athletes. Various reports described the misuse of insulin to improve performance and muscle strength, and synthetic analogs were the subject of several studies describing the beneficial effects of biotechnologically modified insulins. Rapid- or long-acting insulins were developed to enhance the injection-to-onset profile as well as the controllability of administered insulin, where the slightest alterations in primary amino acid sequences allowed the inhibition of noncovalent aggregation of insulin monomers (rapid-acting analogs) or promoted microprecipitation of insulin variants upon subcutaneous application (long-acting analogs). Information on the metabolic fate and renal elimination of insulins has been rather limited, and detection assays for doping control purposes were primarily established using the intact compounds as target analytes in plasma and urine specimens. However, recent studies revealed the presence of urinary metabolites that have been implemented in confirmation methods of sports drug testing procedures. So far, no screening tool is available providing fast and reliable information on possible insulin misuse; only sophisticated procedures including immunoaffinity purification followed by liquid chromatography and tandem mass spectrometry have enabled the unambiguous detection of synthetic insulins in doping control blood or urine samples.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abel JJ (1926) Crystalline insulin. Proc Natl Acad Sci USA 12:132–136
Ashcroft FM (1988) Adenosine 5′-triphosphate-sensitive potassium channels. Annu Rev Neurosci 11:97–118
Ashcroft FM, Rorsman P (1989) Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 54:87–143
Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221–229
Barnett AH, Owens DR (1997) Insulin analogues. Lancet 349:47–51
Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H (2005a) Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 113:435–443
Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH (2005b) A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 113:292–297
Benzi L, Cecchetti P, Ciccarone AM, Di Cianni G, Iozzi LC, Caricato F, Navalesi R (1990) Insulin degradation in vivo: a high-performance liquid chromatographic analysis. J Chromatogr 534:37–46
Biolo G, Wolfe RR (1993) Insulin action on protein metabolism. Baillieres Clin Endocrinol Metab 7:989–1005
Biolo G, Declan Fleming RY, Wolfe RR (1995) Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. J Clin Invest 95:811–819
Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K (2005) Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 28:2100–2105
Dawson RT, Harrison MW (1997) Use of insulin as an anabolic agent. Br J Sports Med 31:259
Dole M, Mack LL, Hines RL, Mobley RC, Ferguson LD, Alice MB (1968) Molecular beams of macroions. J Chem Phys 49:2240–2249
Duckworth WC (1988) Insulin degradation: mechanisms, products, and significance. Endocr Rev 9:319–345
Duckworth WC, Kitabchi AE (1981) Insulin metabolism and degradation. Endocr Rev 2:210–233
Duckworth WC, Hamel FG, Liepnieks J, Frank BH, Yagil C, Rabkin R (1988) High performance liquid chromatographic analysis of insulin degradation products from a cultured kidney cell line. Endocrinology 123:2701–2708
Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19:608–624
Evans PJ, Lynch RM (2003) Insulin as a drug of abuse in body building. Br J Sports Med 37:356–357
Fabris D, Fenselau C (1999) Characterization of allosteric insulin hexamers by electrospray ioniziation mass spectrometry. Anal Chem 71:384–387
Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM (1989) Electrospray ionization for mass spectrometry of large biomolecules. Science 246:64–71
Fujita S, Rasmussen BB, Cadenas JG, Grady JJ, Volpi E (2006) Effect of insulin on human skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood flow and amino acid availability. Am J Physiol Endocrinol Metab 291:E745–E754
Garlick PJ, Grant I (1988) Amino acid infusion increases the sensitivity of muscle protein synthesis in vivo to insulin. Effect of branched-chain amino acids. Biochem J 254:579–584
Halse R, Bonavaud SM, Armstrong JL, McCormack JG, Yeaman SJ (2001) Control of glycogen synthesis by glucose, glycogen, and insulin in cultured human muscle cells. Diabetes 50:720–726
IDF (2006) Diabetes epidemic out of control. http://www.idf.org/home/index.cfm?unode = 7F22F450-B1ED-43BB-A57C-B975D16A812D. Cited 30 April 2007
Iribarne JV, Thomson BA (1976) Evaporation of small ions from charged droplets. J Chem Phys 64:2287–2294
Kebarle P, Ho Y (1997) On the mechanism of electrospray mass spectrometry. In: Cole RB (ed) Electrospray ionization mass spectrometry – fundamentals. Instrumentation and applications. Wiley, New York, pp 3–63
Levin SR, Karam JH, Hane S, Grodsky GM, Forsham PH (1971) Enhancement of arginine-induced insulin secretion in man by prior administration of glucose. Diabetes 20:171–176
Lindström T, Hedman CA, Arnqvist HJ (2002) Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs. Diabetes Care 25:1049–1054
Loo JA, Edmonds CG, Smith RD (1993) Tandem mass spectrometry of very large molecules. 2. Dissociation of multiply charged proline-containing proteins from electrospray ionization. Anal Chem 65:425–438
Manninen AH (2006) Hyperinsulinaemia, hyperaminoacidaemia and post-exercise muscle anabolism: the search for the optimal recovery drink. Br J Sports Med 40:900–905
Mark M (2002) Sulfonylharnstoffe und Glinide. Pharm Unserer Zeit 31:252–262
Plum A, Agers H, Andersen L (2000) Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs. Drug Metab Dispos 28:155–160
Proks P, Lippiat JD (2006) Membrane ion channels and diabetes. Curr Pharm Des 12:485–501
Rasmussen H, Zawalich KC, Ganesan S, Calle R, Zawalich WS (1990) Physiology and pathophysiology of insulin secretion. Diabetes Care 13:655–666
Reichlin S (1983) Somatostatin (second of two parts). N Engl J Med 309:1556–1563
Reverter JL, Tural C, Rosell A, Dominguez M, Sanmarti A (1994) Self-induced insulin hypoglycemia in a bodybuilder. Arch Intern Med 154:225–226
Rich JD, Dickinson BP, Merriman NA, Thule PM (1998) Insulin use by bodybuilders. JAMA 279:1613
Rooyackers OE, Nair KS (1997) Hormonal regulation of human muscle protein metabolism. Annu Rev Nutr 17:457–485
Rosak C (2001) Insulinanaloga: Struktur, Eigenschaften und therapeutische Indikationen (Teil 1: Kurzwirkende Insulinanaloga). Der Internist 42:1523–1535
Rosenfeld L (2002) Insulin: discovery and controversy. Clin Chem 48:2270–2288
Ryle AP, Sanger F, Smith LF, Kitai R (1955) The disulphide bonds of insulin. Biochem J 60:541–556
Sanger F (1959) Chemistry of insulin; determination of the structure of insulin opens the way to greater understanding of life processes. Science 129:1340–1344
Sanger F (1988) Sequences, sequences, and sequences. Annu Rev Biochem 57:1–28
Schäfer EA (1916) The endocrine organs: an introduction to the study of internal secretion. Longmans, Green, Longmans, Green
Seabright PJ, Smith GD (1996) The characterization of endosomal insulin degradation intermediates and their sequence of production. Biochem J 320(Pt 3):947–956
Shapiro ET, Tillil H, Miller MA, Frank BH, Galloway JA, Rubenstein AH, Polonsky KS (1987) Insulin secretion and clearance. Comparison after oral and intravenous glucose. Diabetes 36:1365–1371
Sonksen PH (2001) Hormones and sport (insulin, growth hormone and sport). J Endocrinol 170:13–25
Steiner A, Wagner RA (2002) Insulin. ISP-Verlag, Arnsberg 3:4–73
Tanaka K, Waki H, Ido Y, Akita S, Yoshida Y, Yohida T (1988) Protein and polymer analyses up to m/z 100, 000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2:151–153
Thevis M, Schänzer W (2005a) Examples of doping control analysis by liquid chromatography-tandem mass spectrometry: ephedrines, beta-receptor blocking agents, diuretics, sympathomimetics, and cross-linked hemoglobins. J Chromatogr Sci 43:22–31
Thevis M, Schänzer W (2005b) Identification and characterization of peptides and proteins in doping control analysis. Curr Proteom 2:191–208
Thevis M, Schänzer W (2005c) Mass spectrometry in doping control analysis. Curr Org Chem 9:825–848
Thevis M, Schänzer W (2007a) Current role of LC-MS(/MS) in doping control. Anal Bioanal Chem 388:1351–1358
Thevis M, Schänzer W (2007b) Mass spectrometric identification of peptide hormones in doping control analysis. Analyst 132:287–291
Thevis M, Schänzer W (2007c) Mass spectrometry in sports drug testing: Structure characterization and analytical assays. Mass Spectrom Rev 26:79–107
Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W (2005) Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal Chem 77:3579–3585
Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W (2006) Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry. Anal Chem 78:1897–1903
Thevis M, Loo JA, Loo RR, Schänzer W (2007) Recommended criteria for the mass spectrometric identification of target peptides and proteins (<8 kDa) in sports drug testing. Rapid Commun Mass Spectrom 21:297–304
Thomas A, Thevis M, Delahaut P, Bosseloir A, Schanzer W (2007) Mass spectrometric identification of degradation products of insulin and its long-acting analogues in human urine for doping control purposes. Anal Chem 79:2518–2524
Tillil H, Shapiro ET, Miller MA, Karrison T, Frank BH, Galloway JA, Rubenstein AH, Polonsky KS (1988) Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol 254:E349–E357
Tipton KD, Wolfe RR (2001) Exercise, protein metabolism, and muscle growth. Int J Sport Nutr Exerc Metab 11:109–132
von Mering J, Minkowski O (1889) Diabetes mellitus nach Pankreasextirpation. Centralblatt für klinische Medicin 10:393–394
WADA (2007) The 2007 Prohibited List. http://www.wada-ama.org/rtecontent/document/2007_List_En.pdf. Cited 30 January 2007
Wolfe RR (2000) Effects of insulin on muscle tissue. Curr Opin Clin Nutr Metab Care 3:67–71
Wolfe RR (2005) Regulation of skeletal muscle protein metabolism in catabolic states. Curr Opin Clin Nutr Metab Care 8:61–65
Yeaman SJ, Armstrong JL, Bonavaud SM, Poinasamy D, Pickersgill L, Halse R (2001) Regulation of glycogen synthesis in human muscle cells. Biochem Soc Trans 29:537–541
Young J, Anwar A (2007) Strong diabetes. Br J Sports Med 41:335–336; discussion 336
Zhang XJ, Chinkes DL, Wolf SE, Wolfe RR (1999) Insulin but not growth hormone stimulates protein anabolism in skin wound and muscle. Am J Physiol 276:E712–E720
Acknowledgments
The authors thank the Manfred-Donike Institute for Doping Analysis for supporting the presented work.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Thevis, M., Thomas, A., Schänzer, W. (2010). Insulin. In: Thieme, D., Hemmersbach, P. (eds) Doping in Sports: Biochemical Principles, Effects and Analysis. Handbook of Experimental Pharmacology, vol 195. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79088-4_10
Download citation
DOI: https://doi.org/10.1007/978-3-540-79088-4_10
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79087-7
Online ISBN: 978-3-540-79088-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)